Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 6/20 | 0.88 |
| ▸ | OXTR | P30559 | 15/20 | 0.88 |
| ▸ | AVPR2 | P30518 | 5/20 | 0.88 |
| ▸ | AVPR1B | P47901 | 5/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Demoxytocin SCHEMBL29376547 | 1.00 | AVPR1A (0.88) | AVPR1AOXTRAVPR2AVPR1B | |
| Demoxytocin SCHEMBL38442 | 1.00 | AVPR1A (0.88) | AVPR1AOXTRAVPR2AVPR1B | |
| Oxytocin SCHEMBL28086558 | 0.97 | OXTR (0.93) | AVPR1AOXTRAVPR2AVPR1B | |
| Oxytocin Trisulfide SCHEMBL30712243 | 0.97 | AVPR1A (0.86) | AVPR1AOXTRAVPR2AVPR1B | |
| SCHEMBL15511632 | 0.95 | AVPR1A (0.80) | AVPR1AOXTRAVPR2AVPR1B | |
| SCHEMBL22333521 | 0.95 | AVPR1A (0.79) | AVPR1AOXTRAVPR2AVPR1B | |
| SCHEMBL15511860 | 0.94 | OXTR (0.81) | AVPR1AOXTRAVPR2AVPR1B | |
| SCHEMBL15511596 | 0.94 | AVPR1A (1.00) | AVPR1AOXTRAVPR2AVPR1B | |
| Oxytocin SCHEMBL29048 | 0.94 | OXTR (1.00) | AVPR1AOXTRAVPR2AVPR1B | |
| Oxytocin SCHEMBL21527573 | 0.94 | OXTR (1.00) | AVPR1AOXTRAVPR2AVPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 499 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025245322-A1 | OXYTOCIN-BASED THERAPEUTICS TO IMPROVE COGNITIVE CONTROL IN INDIVIDUALS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER | THE GENERAL HOSPITAL CORPORATION (US) | 2025-11-27 | — | — | WO | claimed |
| EP-4313106-B1 | TREATMENT OF DYSPHAGIA | OT4B (FR) | 2025-01-15 | — | — | EP | claimed |
| US-20240277624-A1 | NEW FORMULATIONS COMPRISING BIOLOGIC ACTIVE DRUGS | NANEXA AB (SE) | 2024-08-22 | — | — | US | claimed |
| US-20240197813-A1 | TREATMENT OF DYSPHAGIA | CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE (FR) | 2024-06-20 | — | — | US | claimed |
| EP-4351529-A1 | NEW FORMULATIONS COMPRISING BIOLOGIC ACTIVE DRUGS | Nanexa AB (SE) | 2024-04-17 | — | — | EP | claimed |
| US-20230381267-A1 | OXYTOCIN TREATMENT FOR HYPERMOBILE EHLERS-DANLOS SYNDROME | BAYLOR COLLEGE OF MEDICINE | 2023-11-30 | — | — | US | claimed |
| EP-4221834-A1 | OXYTOCIN TREATMENT FOR HYPERMOBILE EHLERS-DANLOS SYNDROME | Baylor College of Medicine (US) | 2023-08-09 | — | — | EP | claimed |
| WO-2022258985-A1 | NEW FORMULATIONS COMPRISING BIOLOGIC ACTIVE DRUGS | NANEXA AB (SE) | 2022-12-15 | — | — | WO | claimed |
| WO-2022073008-A1 | OXYTOCIN TREATMENT FOR HYPERMOBILE EHLERS-DANLOS SYNDROME | BAYLOR COLLEGE OF MEDICINE (US) | 2022-04-07 | — | — | WO | claimed |
| US-20210346621-A1 | INTRANASAL ADMINISTRATION | Optinose, Inc. | 2021-11-11 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| US-20100035805-A1 | NON-AQUEOUS LIQUID FORMULATION FOR NASAL OR BUCCAL ADMINISTRATION | OPTINOSE AS (NO) | 2010-02-11 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007141541-A1 | INTRANASAL ADMINISTRATION | OPTINOSE AS (NO) | 2007-12-13 | — | — | WO | claimed |
| WO-2007125318-A1 | NON-AQUEOUS LIQUID FORMULATION FOR NASAL OR BUCCAL ADMINISTRATION | OPTINOSE AS (NO) | 2007-11-08 | — | — | WO | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20050048164-A1 | Chewing gum core overcoated with active powder materials containing anseptics, cooling compound, flavor intensifier, sweetening , enzyme, drug | STAHL BRONISLAW-JAN (DK) | 2005-03-03 | — | — | US | claimed |
| EP-1495681-A2 | A coated chewing gum, a method for preparation thereof and the use of one or more active substances in the coating | DANDY A/S (DK) | 2005-01-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197813-A1 | TREATMENT OF DYSPHAGIA | OXTR, GRPR, NTSR2 | AVPR1A 22/4885OXTR 1/4885AVPR2 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.